Yeast System Rapidly Generates Potent Antibodies
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Yeast System Rapidly Generates Potent Antibodies
- A new technology called Autonomous Hypermutation Yeast Surface Display (AHEAD) can generate high-affinity antibody clones in as little as two weeks.
- This method, developed by a team including researchers from the University of California, Irvine and Harvard Medical School, mimics somatic hypermutation observed in animal immune systems.
Full Summary — powered by AI
Generating effective antibodies is crucial for various applications, including basic research, diagnostics, and therapeutic development. Traditionally, animal immunization has been the primary method for producing antibodies, yielding highly selective and potent clones through a natural process called somatic hypermutation. However, this approach is often slow, can be inaccessible, and may not be compatible with all types of antigens.
To address these limitations, researchers have developed Autonomous Hypermutation Yeast Surface Display (AHEAD). This synthetic recombinant antibody generation technology engineered yeast to mimic somatic hypermutation. In the AHEAD system, antibody fragments are encoded on an error-prone orthogonal DNA replication system. This setup allows surface-displayed antibody repertoires to continuously mutate as the yeast cells are cultured. Through cycles of yeast culturing and enrichment for antigen binding, the system can produce high-affinity antibody clones in as little as two weeks.
The effectiveness of AHEAD was demonstrated by generating potent nanobodies against the SARS-CoV-2 S glycoprotein, as well as against a G-protein-coupled receptor and other targets. This technology was developed by a team including co-principal investigator Chang Liu, an associate professor of biomedical engineering at the University of California, Irvine. The research, initially posted as a preprint in November 2020, offers a streamlined approach for rapid antibody generation.